Pipeline
Our Pipeline is comprised of Biologics, including the proprietary BEAT® MultispecificsTM platform, and one Cbl-b inhibitor small molecule targeting the spectrum of hematological cancers and solid tumors. If you are interested in exploring a partnership, Contact us.
Oncology
- Overview
- ISB 2001
Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors
ASSETS | DESCRIPTION | INDICATION |
---|---|---|
CLINICAL ASSETS |
PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
---|---|---|---|
STATUS |
---|
ISB 2001
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager
PHASE 1
ORPHAN DRUG
GRC 65327
Cbl-b Inhibitor Small Molecule
Solid Tumors
PRE-CLINICAL
CANDIDATES |
---|
ISB 2301
Solid Tumors
DISCOVERY
PRODUCTS
COMPOUND
CLINICAL ASSETS
ISB 2001
TARGET
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager
INDICATION
Multiple Myeloma
PHASE
STATUS :
PHASE 1 ORPHAN DRUG
PRODUCTS
COMPOUND
CLINICAL ASSETS
GRC 65327
TARGET
Cbl-b Inhibitor Small Molecule
INDICATION
Solid Tumors
PHASE
STATUS :
PRE-CLINICAL
PRODUCTS
COMPOUND
CANDIDATES
ISB 2301
TARGET
IMMUNITE™
NK-Cell Engager
INDICATION
Solid Tumors
PHASE
STATUS :
DISCOVERY
ISB 2001 is first TREATTM Trispecific Antibody for
Relapsed/Refractory Multiple Myeloma
- BCMA and CD38 are expressed on the surface of multiple myeloma cells
and are clinically validated targets.
- ISB 2001 combines three proprietary Fab arms binding to CD3 on T-cells, and to BCMA and CD38 on myeloma cells.
- In vitro studies showed increased killing potency of tumor cells compared to all tested antibodies, including currently approved and investigational multiple myeloma therapies.
- In vivo studies in multiple myeloma models also show superior potency relative to antibodies for the treatment of multiple myeloma.
- ISB 2001 redirects CD3+ T lymphocytes to kill tumor cells expressing from low
to high levels of both BCMA and CD38. - With two different tumor-associated antigens, ISB 2001 is expected to be more resistant to antigen escape associated with treatment of MM patients
. - ISB 2001 was granted ODD by the U.S. FDA

AML: Acute Myeloid Leukemia
For collaborations, please contact us here.
Diversity of Immune Cell Engagement and Indications across Hematologic and Solid Tumors
ASSETS | DESCRIPTION | INDICATION |
---|---|---|
CLINICAL ASSETS |
PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
---|---|---|---|
STATUS |
---|
ISB 2001
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager
PHASE 1
ORPHAN DRUG
GRC 65327
Cbl-b Inhibitor Small Molecule
Solid Tumors
PRE-CLINICAL
CANDIDATES |
---|
ISB 2301
Solid Tumors
DISCOVERY
PRODUCTS
COMPOUND
CLINICAL ASSETS
ISB 2001
TARGET
BCMA x CD38 x CD3 TREAT ™
trispecific T-Cell Engager
INDICATION
Multiple Myeloma
PHASE
STATUS :
PHASE 1 ORPHAN DRUG
PRODUCTS
COMPOUND
CLINICAL ASSETS
GRC 65327
TARGET
Cbl-b Inhibitor Small Molecule
INDICATION
Solid Tumors
PHASE
STATUS :
PRE-CLINICAL
PRODUCTS
COMPOUND
CANDIDATES
ISB 2301
TARGET
IMMUNITE™
NK-Cell Engager
INDICATION
Solid Tumors
PHASE
STATUS :
DISCOVERY
ISB 1442 - Triple Mechanism of Tumor-Cell Killing
Enhanced ADCP, ADCC and CDC
- Dual binding to CD38 and CD47 epitopes, increasing avidity relative to daratumumab
- Two Fab regions drive binding to distinct CD38 epitopes that don’t compete functionally with daratumumab
- One arm blocks CD47-SIRPa binding on tumor cells to enhance ADCP
- Enhanced phagocytosis by blocking CD47 and increasing activation signaling through FcγR binding
- CD47 is over-expressed by hematologic tumors and associated with worse prognosis
- Reduced potential for antigen sink with lower-affinity Fab binding to CD47 expressed on healthy cells
- Potent ADCC, CDC and ADCP based on optimized affinity, architecture/avidity and enhanced
Fc function
- Optimized tolerability with low potential for adverse effects on red blood cells such as hemagglutination, platelet aggregation
- ISB 1442 was granted Orphan Drug Designation for Multiple Myeloma by the U.S. FDA

TREAT™: Trispecific Engagement by Antibodies based on the TCR, MHC: Major histocompatibility complex, CDC: Complement-Dependent Cytotoxicity ADCC: Antibody-Dependent Cell-mediated Cytotoxicity
ISB 2001 is first TREATTM Trispecific Antibody for
Relapsed/Refractory Multiple Myeloma
- BCMA and CD38 are expressed on the surface of multiple myeloma cells
and are clinically validated targets.
- ISB 2001 combines three proprietary Fab arms binding to CD3 on T-cells, and to BCMA and CD38 on myeloma cells.
- In vitro studies showed increased killing potency of tumor cells compared to all tested antibodies, including currently approved and investigational multiple myeloma therapies.
- In vivo studies in multiple myeloma models also show superior potency relative to antibodies for the treatment of multiple myeloma.
- ISB 2001 redirects CD3+ T lymphocytes to kill tumor cells expressing from low
to high levels of both BCMA and CD38. - With two different tumor-associated antigens, ISB 2001 is expected to be more resistant to antigen escape associated with treatment of MM patients
. - ISB 2001 was granted ODD by the U.S. FDA

Inflammation and Autoimmune Disease
The autoimmune disease assets have been out-licensed to enable greater focus on oncology. Explore the pipeline chart below to learn more and Contact Us for additional information.
Autoimmune Disease
PRODUCTS
Telazorlimab (and ISB 830-X8)
DESCRIPTION
OX40 antagonist
Monoclonal Antibody
Atopic Dermatitis*
PRODUCTS | DESCRIPTION | |
---|---|---|
PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
---|---|---|---|
STATUS |
---|
Licensed to
$320 million for upfront payment, development, regulatory and sales milestone payments,
plus tiered royalties on global sales
Licensed to
€20.8 million for upfront payment. Plus development, regulatory and sales milestone payments,
and tiered royalties on global sales
Partnering-Ready Assets to Accelerate Short-Term Value Creation
PRODUCTS
ASSETS
CLINICAL ASSETS
ISB 1342
DESCRIPTION
CD38 x CD3 BEAT® bispecific T-Cell Engager
INDICATION
Multiple Myeloma
PHASE
STATUS :
PHASE 1 ORPHAN DRUG
PRODUCTS
ASSETS
CLINICAL ASSETS
ISB 1442
DESCRIPTION
CD38 biparatopic x CD47 BEAT® Myeloid-Cell Engager
INDICATION
Multiple Myeloma; AML planned
PHASE
STATUS :
PHASE 1 ORPHAN DRUG
ASSETS | DESCRIPTION | INDICATION |
---|---|---|
CLINICAL ASSETS |
PRECLINICAL | PHASE 1 | PHASE 2 | PHASE 3 |
---|---|---|---|
STATUS |
---|
PHASE 1
ORPHAN DRUG
PHASE 1
ORPHAN DRUG